CBD for Rheumatoid Arthritis

Recruiting in Palo Alto (17 mi)

Overseen by Veena Ranganath, MD, MS

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1

Waitlist Available

Sponsor: University of California, Los Angeles

Stay on Your Current Meds

Approved in 3 Jurisdictions

Trial Summary

What is the purpose of this trial?

This trial tests if CBD can help RA patients who are already on stable therapy by reducing their pain and inflammation. Patients will take either CBD or a non-active substance for a few months to see if it makes a difference.

Research Team

Ziva Cooper, PhD

Principal Investigator

University of California, Los Angeles

Veena Ranganath, MD, MS

Principal Investigator

University of California, Los Angeles

Eligibility Criteria

Adults with active Rheumatoid Arthritis (RA) who have been on stable RA therapy for at least 12 weeks can join this trial. They must not have used cannabis recently, be free of chronic infections or substance use disorders, and agree to effective contraception if they are capable of childbearing.

Inclusion Criteria

Meet the American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) 2010 Classification Criteria for Rheumatoid Arthritis

My rheumatoid arthritis treatment has been the same for the last 12 weeks.

Power Doppler Score >= 5 (for the PDUS 34 joint score)

Exclusion Criteria

I am sexually active and not using birth control.

I am not pregnant, planning to become pregnant, or breastfeeding.

My liver function is moderately or severely impaired.

Treatment Details

Interventions

• Cannabidiol (Cannabinoid)

Trial Overview The study is testing the effectiveness and safety of two different doses of Cannabidiol (CBD), compared to a placebo, in patients with RA. Participants will continue their regular RA treatments while adding either CBD or placebo capsules twice daily.

Participant Groups

Group I: 400 mg CBD twice daily Experimental Treatment 1 Intervention

Participants will take capsules containing cannabidiol amounting to 400mg CBD twice daily

Group II: 200mg CBD twice daily Experimental Treatment 1 Intervention

Participants will take capsules containing cannabidiol amounting to 200mg CBD twice daily

Group III: Placebo Placebo Group 1 Intervention

Participants will take capsules containing medium chain triglyceride (MCT) oil

Who Is Running the Clinical Trial?

University of California, Los Angeles

Lead Sponsor

Trials

1,594

Recruited

10,430,000+

Dr. Thomas Rando

University of California, Los Angeles

Chief Medical Officer since 2023

MD from UCLA

Amir Naiberg

University of California, Los Angeles

Chief Executive Officer since 2024

JD from UCLA